Oya1
Ebola
About OyaGen
OyaGen is a privately held, preclinical-stage biotechnology company founded in 2003 with a dual focus on proprietary drug discovery and contract research services. Its core pipeline targets viral infections, including HIV, Ebola, and coronaviruses, with a platform aimed at disabling key viral proteins. The company operates from a state-of-the-art lab in the Rochester BioVenture Center and is seeking significant capital to advance its lead HIV candidate into clinical trials while exploring strategic partnerships or M&A.
View full company profileAbout OyaGen
OyaGen is a privately held, preclinical-stage biotechnology company founded in 2003 with a dual focus on proprietary drug discovery and contract research services. Its core pipeline targets viral infections, including HIV, Ebola, and coronaviruses, with a platform aimed at disabling key viral proteins. The company operates from a state-of-the-art lab in the Rochester BioVenture Center and is seeking significant capital to advance its lead HIV candidate into clinical trials while exploring strategic partnerships or M&A.
View full company profileTherapeutic Areas
Other Ebola Drugs
| Drug | Company | Phase |
|---|---|---|
| Vaxine Ebola Vaccine | Vaxine | Preclinical |